The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.
According to Frost & Sullivan:
“The Frost & Sullivan Best Practices awards have identified and honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.”
This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.
Avance Clinical CEO Yvonne Lungershausen commended her team of more than 100 clinical trial specialists throughout Australia and New Zealand.
“We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.”
“Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials.”
“Avance Clinical are experts in facilitating fast study start-up with trials typically approved and initiated in under 6 weeks.”
Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
Avance specialises in supporting biotech companies with their early phase clinical trials having conducted over 150 early phase (Phase 1 and 2) trials in the past 4 years involving treatment of over 8,300 participants across 95 therapeutic indications.
According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:
“Within Asia-Pacific’s highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. The company offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance.
Avance Clinical is a full-service CRO with a 20-year track-record.
The company has grown quickly over the past year doubling staff numbers and with plans to further expand in the region. Avance Clinical offers a real size match for biotechs that means better mission understandings and stronger customer service compared to some of the larger CROs.
Avance’s reputation for high-quality clinical trial outcomes leveraging its scientific and regulatory expertise has attracted an impressive 74% repeat business rate, underscoring the company’s position as a market leader.”
In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high-quality sites and attractive cost of running trials in Australia including:
- The Australian Government financial rebate of up to 43.5% on clinical trial spend
- No IND required for clinical trials and streamlined regulatory processes
- Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities
Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.
For more information about the benefits of running your next study with Avance Clinical, please fill out the enquiry form attached to this page.